What comes after the maximum dose of a GLP-1?

The short answer

Wegovy HD (semaglutide 7.2 mg) is the first FDA-approved step above the standard 2.4 mg Wegovy dose. It is meant for adults who have tolerated 2.4 mg for at least four weeks and still need more weight reduction. It adds roughly three percentage points of weight loss on average, at the price of more side effects, especially altered skin sensation.

Evidence tier: Tier 1–2. The 7.2 mg dose is supported by a 72-week randomized phase 3b trial and an FDA approval in March 2026. Tirzepatide has no approved dose above 15 mg.

The main points:

• "What's next after the top dose?" now has a regulated answer for semaglutide — a higher approved dose, prescribed deliberately rather than improvised.
• The benefit is real but modest — about 3 extra percentage points versus 2.4 mg, not a different drug.
• The cost is a distinct side-effect signal — altered skin sensation was several times more common at 7.2 mg, and the FDA says it is still investigating.
• For tirzepatide, 15 mg is the ceiling on the label — going beyond it means off-label or unregulated territory.

This sits alongside our titration schedule guide and the dosing mistakes guide; read those first if you are still climbing the standard ladder.

Why do people ask what comes after the top dose?

Evidence tier: Tier 4–5 (community signal). Forum questions are a measure of what people are asking, not of what works.

In community forums, a recurring question is some version of "What's next after 15 mg?" or "I'm at the top dose and my loss has stalled — now what?" People who have climbed the whole standard ladder reach the highest labeled dose, and some find that weight loss slows or stops there. Because the drugs are dose-responsive in the trials, it is natural to wonder whether another step up exists.

Two things are worth separating. First, a slowdown at the top dose is usually not a dose problem; it is the normal shape of weight loss, which is non-linear and tends to flatten as the body defends a lower weight. Our plateau guide covers why escalation often backfires as a response to a plateau. Second, a genuinely incomplete response at a well-tolerated top dose is a legitimate clinical question — and for semaglutide there is now an approved answer. That answer is a prescriber's decision, not a do-it-yourself escalation.

What is Wegovy HD and who is it for?

Evidence tier: Tier 1. Regulatory facts from the FDA press announcement (March 19, 2026) and the manufacturer's release; indication wording is the FDA's.

On March 19, 2026, the FDA approved a new higher dose (7.2 mg) of Wegovy, marketed as Wegovy HD. The agency said the decision came 54 days after filing, under its National Priority Voucher pilot program, and described the indication as reducing excess body weight and maintaining weight reduction long-term in adults with obesity, or overweight with at least one weight-related condition.

The manufacturer's announcement adds the practical gate: use with a reduced-calorie diet and increased physical activity, provided the person has tolerated the 2.4 mg dose for at least four weeks and additional weight reduction is clinically indicated. In other words, it is a step for people who are already on the maintenance dose, doing well on tolerability, and still have a clinical reason to want more — not a starting point and not a shortcut. The exact dose steps and timing for moving from 2.4 mg to 7.2 mg are in the prescribing information, and that document, not a blog or a forum thread, is the source to follow. We have deliberately not restated a schedule here.

For background on the drug itself, see our semaglutide deep dive.

How much extra weight loss does 7.2 mg actually add?

Evidence tier: Tier 1. STEP UP is a randomized, double-blind, placebo- and active-controlled phase 3b trial, published in The Lancet Diabetes & Endocrinology.

The pivotal data are from STEP UP, a 72-week trial in 1,407 adults with a BMI of 30 or higher and without diabetes, randomized in a 5:1:1 ratio to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo (Wharton et al., 2025). In the published abstract, mean body-weight change was −18.7% with 7.2 mg versus −15.6% with 2.4 mg, an estimated treatment difference of −3.1 percentage points (95% CI −4.7 to −1.6; p<0.0001).

The manufacturer reports the same pattern under two analysis conventions. If everyone stayed on treatment, mean loss was about 20.7% at 7.2 mg, 17.5% at 2.4 mg and 2.4% on placebo; regardless of adherence it was about 18.8%, 15.5% and 3.9%. About 31% of people on 7.2 mg lost at least 25% of their body weight, compared with about 15% on 2.4 mg and none on placebo.

Two cautions help keep these numbers in proportion. The comparison that matters for "should I go higher?" is 7.2 mg versus 2.4 mg, and that gap is roughly three percentage points on average — a meaningful improvement for some people, but nowhere near a doubling. And these are averages in a trial population that tolerated the escalation; individual results spread widely around them. For people with type 2 diabetes, a companion trial (STEP UP T2D) tested the same dose in that population (Lingvay et al., 2025); we have not summarized its weight results here because we could not verify them from the full abstract.

What are the downsides of going higher?

Evidence tier: Tier 1–2. Adverse-event rates come from the trials and manufacturer disclosures; the FDA states it is still investigating the skin-sensation reaction.

The expected gastrointestinal effects remain the most common: the FDA lists nausea, vomiting, diarrhea, constipation and abdominal pain. These are the same family of effects covered in our side effects guide and nausea guide.

The newer signal is altered skin sensation — sensitivity, pain or burning, reported as dysesthesia, paresthesia or hyperesthesia. The FDA says these reactions were common, occurred more often at the higher dose, and generally resolved on their own or with dose reduction, and that it is conducting further investigations. The manufacturer reports altered skin sensation events in about 22% of people on 7.2 mg, 6% on 2.4 mg and 0.3% on placebo. In the type 2 diabetes trial's abstract, dysesthesia occurred in 18.9% of 307 participants on 7.2 mg, 4.9% of 103 on 2.4 mg and none on placebo.

The manufacturer's list of most common adverse reactions at 7.2 mg also includes fatigue, headache, dizziness, hair loss and flatulence. The standard class warnings still apply, including the boxed warning on thyroid C-cell tumors, and cautions on pancreatitis, gallbladder disease, dehydration and kidney problems, and increased heart rate. We did not find discontinuation rates in the sources we could read, so we are not quoting one.

Can you simply take more than the top dose yourself?

Evidence tier: Tier 1 for the regulatory position; Tier 5 for anything about self-directed escalation, where no trial data exist.

Not safely, and this is where the "what's next?" question can go wrong. The approved higher semaglutide dose exists because a trial tested a defined escalation under supervision and a regulator reviewed the result. That is very different from taking extra units from a pen or vial. Pens deliver fixed doses, so "going higher" with a pen is not a thing a person can do correctly, and with compounded or gray-market vials the arithmetic of units, concentration and volume is exactly where serious errors happen — see our guide to GLP-1 dosing mistakes.

For tirzepatide, the labeled ceiling remains 15 mg. In the pivotal SURMOUNT-1 trial, mean weight loss was about 15% at 5 mg, around 19–20% at 10 mg and roughly 20% or more at 15 mg (Jastreboff et al., 2022); we found no approved dose beyond that, so anyone exceeding 15 mg is outside both the label and the evidence base. If you are at the top of the ladder on any GLP-1, the options that are actually supported are staying on a tolerable dose, addressing diet, protein and resistance training (see muscle preservation), or discussing a switch with your prescriber (see switching between GLP-1s).

How should you decide whether a higher dose makes sense?

Evidence tier: Tier 3–4. This is a practical framework drawn from the trial design and label conditions, not a validated decision rule.

A reasonable conversation with a prescriber would cover four questions. Have you been on the current top dose long enough, and consistently, to judge it? The Wegovy HD indication itself requires at least four weeks of tolerated 2.4 mg, and slowdowns in the first weeks of any dose are common. Is the slowdown a plateau you can explain, such as reduced intake, a missed dose, or ordinary adaptation? Are you tolerating the current dose well, since the approved path assumes you are? And would a further modest average gain be worth a higher chance of GI effects and altered skin sensation?

If the answer to the last question is "not sure," that is a reasonable place to stop. Many people do well at the maintenance dose, and the titration guide notes that you do not have to climb to the maximum just because higher steps exist. If you have already been through a long run on one drug with a falling response, our tolerance and "does it stop working" article discusses what the evidence does and does not show.

Limitations

This is an educational guide, not medical advice or a dosing prescription.

• We did not read the full prescribing information or full-text trial papers, so dose-escalation steps, discontinuation rates and some trial figures are either quoted from press releases and abstracts or deliberately omitted.
• Manufacturer-reported numbers (including the altered-skin-sensation rates and the analysis-convention figures) come from a press release and are not independently verified here.
• STEP UP enrolled adults without diabetes; results may differ in other populations, and the type 2 diabetes trial's weight results are not summarized here.
• The FDA is still investigating the skin-sensation reaction, so the safety picture for 7.2 mg may change.
• Availability, pricing and coverage change quickly; check current status with your prescriber and pharmacy.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

For people on semaglutide who have tolerated the 2.4 mg dose and still have a clinical reason to want more, there is now an approved, trial-tested next step: Wegovy HD at 7.2 mg. It adds about three percentage points of average weight loss over 2.4 mg in the pivotal trial, and in exchange brings more side effects, with altered skin sensation the new one to know about. For tirzepatide, 15 mg is where the label ends.

The practical takeaway is to treat "what's after the max dose?" as a conversation with your prescriber, not a calculation. A slowdown at the top is often a plateau rather than a dose problem; a higher approved dose is an option for some, not an obligation for all; and any escalation that is not on a label is a guess with real downsides. The people who tend to do best stay on a dose they can tolerate and sustain, and make changes deliberately, with someone watching the result.

Related on this site

• GLP-1 titration schedules
• GLP-1 dosing mistakes
• GLP-1 weight-loss plateau
• Semaglutide deep dive
• Tirzepatide deep dive
• GLP-1 side effects and how to manage them
• Switching between GLP-1s
• Our evidence-tier framework

References

• Wharton S, Freitas P, Hjelmesæth J, et al. 2025. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 13(11):949-963. PMID 40961952 · doi:10.1016/S2213-8587(25)00226-800226-8)
• Lingvay I, Bergenheim SJ, Buse JB, et al. 2025. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 13(11):935-948. PMID 40961953 · doi:10.1016/S2213-8587(25)00225-600225-6)
• U.S. Food and Drug Administration. 2026 (March 19). FDA approves fourth product under National Priority Voucher program: higher-dose semaglutide.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024.
• Novo Nordisk. 2026 (March 19). FDA approves Wegovy HD (semaglutide 7.2 mg) injection (press release; source of manufacturer-reported analysis-convention and altered-skin-sensation figures).